<DOC>
	<DOCNO>NCT02253277</DOCNO>
	<brief_summary>In study rationale evaluate safety tolerability combine administration nilotinib increase dose ruxolitinib patient chronic myeloid leukemia patient Philadelphia positive acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Safety Tolerability Combined Treatment With Nilotinib Ruxolitinib CML Ph+ ALL Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Patients first stratum must chronic myeloid leukemia receive nilotinib firstline therapy receive secondline subsequentline treatment nilotinib . Patients second stratum must CML AP/BC relapsed/refractory Ph+ ALL , Ph+ ALL patient MRD without prior nilotinib pretreatment ; Patients must adequate end organ function , define : Creatinine &lt; 2.0 x upper limit normal ( ULN ) Total bilirubin &lt; 1.5 x ULN ( &lt; 3.0 x ULN related disease polymorphism , Mb . Gilbert ) ALT AST &lt; 2.5 x ULN ( &lt; 5.0 x ULN related disease ) Serum lipase ≤ 1.5 x ULN Alkaline phosphatase ≤ 2.5 x ULN ( &lt; 5.0 x ULN related disease ) ; Patients must follow electrolyte value within normal limit correct within normal limit supplement prior first dose study medication : Potassium Magnesium Phosphate Total calcium ( correct serum albumin ) ; Female patient childbearing potential ( WOCBP ) must negative serum pregnancy test within 7 day initiation study drug . All WOCBP must use highly effective contraceptive method throughout 3 month study ; Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 patient CP , ≤ 2 patient AP/BC relapsed/refractory Ph+ ALL Ph+ ALL MRD ; Patient follow laboratory value within 7 day start study drug : For CML Ph+ ALL patient : platelet count &gt; 75 x 109/L ANC &gt; 1.0 x 109/L Patient must evidence active malignancy exist CML ALL Patient must receive drug interfere coagulation inhibits platelet function , exception aspirin ≤ 150 mg per day low molecular weight heparin . Patient must history platelet dysfunction , bleed diathesis , and/or coagulopathy 6 month prior screen ; Patient must require treatment strong CYP3A4 inducer inhibitor Patient must history hypersensitivity study drug drug similar chemical class excipients ; Patients must take investigational drug within 28 day prior screen ; Patient must pregnant lactate screen and/or baseline ; Patient must impair cardiac function Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CML , Ph+ ALL</keyword>
</DOC>